These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3886949)

  • 1. [Antibacterial activity of cefmenoxime against clinical isolates. Comparative study].
    Takahashi C; Miyazawa K
    Jpn J Antibiot; 1985 Jan; 38(1):27-30. PubMed ID: 3886949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
    Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
    Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of antibacterial activity of cefmenoxime with other cephalosporins against clinically isolated bacteria (author's transl)].
    Kosakai N; Oguri T
    Jpn J Antibiot; 1981 Oct; 34(10):1366-86. PubMed ID: 6278174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibacterial activities of new cephems against clinically isolated organisms (author's transl)].
    Okada K; Kawamura N; Ohkoshi M; Satake Y; Kawakita J
    Jpn J Antibiot; 1982 Apr; 35(4):1009-21. PubMed ID: 6285019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of in vitro activity of first, second and third generation cephem antibiotics against various pathogens isolated from clinical materials in 1983].
    Matsuo K; Tsuzaki Y; Furukawa S; Uete T
    Jpn J Antibiot; 1984 Jun; 37(6):1040-57. PubMed ID: 6387213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Basic and clinical studies on cefmenoxime in pediatric field].
    Iwata S; Iwasaki Y; Kanemitsu T; Akita H; Hotta M; Yamashita N; Nanri S; Wakabayashi R; Kojima Y; Sunakawa K; Osano M; Ichihashi Y; Tachibana Y; Takahashi H; Kori T
    Jpn J Antibiot; 1982 Oct; 35(10):2440-9. PubMed ID: 6306295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefotaxime, ceftizoxime, cefmenoxime, and latamoxef in comparison with other beta-lactam antibiotics against recent clinical isolates of Haemophilus influenzae and Haemophilus parainfluenzae.
    Kawakami Y; Okimura Y; Horiuchi N; Kanai M
    Microbiol Immunol; 1982; 26(7):617-21. PubMed ID: 6290854
    [No Abstract]   [Full Text] [Related]  

  • 8. [Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution].
    Deguchi K; Fukayama S; Nishimura Y; Nishike A; Oda S; Sato S; Matsumoto Y; Ikegami R; Yokota N; Tanaka S
    Jpn J Antibiot; 1985 Jul; 38(7):1739-49. PubMed ID: 3906166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of in vitro antibacterial activities of new cephems against clinical organisms (isolated between June 1983 and January 1984)].
    Tsuji A; Goto S; Sato K; Tomizawa M; Hasebe S; Takagi T; Yatagai S; Kanno H; Ozaki K; Yakata M
    Jpn J Antibiot; 1985 Aug; 38(8):2171-84. PubMed ID: 3908734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibility of recent clinical isolates of Pseudomonas aeruginosa and Serratia marcescens to cefotaxime, ceftizoxime, cefmenoxime, latamoxef and cefsulodin in comparison with other beta-lactam antibiotics and aminoglycosides].
    Kawakami Y; Okimura Y; Horiuchi N; Kanai M
    Jpn J Antibiot; 1982 Sep; 35(9):2314-7. PubMed ID: 6292543
    [No Abstract]   [Full Text] [Related]  

  • 12. [In vitro bacteriostatic activity of cefmenoxime (SCE 1365), cefotaxime and moxalactam].
    Husson MO; Bryskier A; Izard D; Leclerc H
    Pathol Biol (Paris); 1983 May; 31(5):347-50. PubMed ID: 6312395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1984 May; 37(5):791-801. PubMed ID: 6090721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The antibacterial activity of cefmetazole and other antibiotics to 463 isolates].
    Xu Y; Wang H; Chen M
    Zhonghua Nei Ke Za Zhi; 1997 Aug; 36(8):540-2. PubMed ID: 10436961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro antibacterial activities of cefteram and other beta-lactam agents against recent clinical isolates].
    Yamaguchi K; Ohno A; Takahashi S; Hayashi M; Yamanaka K; Hirakata Y; Mitsuyama J
    Jpn J Antibiot; 1998 Jan; 51(1):11-25. PubMed ID: 9557273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative activity of cefotaxime and selected beta-lactam antibiotics against Haemophilus influenzae and aerobic gram-negative bacilli.
    Dabernat HJ; Delmas C
    Rev Infect Dis; 1982; 4 Suppl():S401-5. PubMed ID: 6294790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of temocillin, moxalactam and cefotaxime against gram negative bacteria sensitive or resistant to ureidopenicillins and/or cefacedone.
    Bartmann K; Tarbuc R
    Zentralbl Bakteriol Mikrobiol Hyg A; 1983 Dec; 256(2):202-10. PubMed ID: 6324518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nationwide study of the antimicrobial susceptibility of clinical isolates of Proteus group in Japan].
    Igari J; Shitara M; Morimoto M; Shiga N; Kosakai N
    Jpn J Antibiot; 1987 Apr; 40(4):823-42. PubMed ID: 3475483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Susceptibility of clinical isolates to aztreonam].
    Nagasawa Z; Nishimura T; Nagumo F; Ueda H; Tadano J; Katoh O; Yamada H
    Jpn J Antibiot; 1989 Jun; 42(6):1257-70. PubMed ID: 2507799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.